Combination chemotherapy before surgery for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- Your tumor is located within 12 cm of the anal margin and is considered locally advanced (stage cT3-4 or cN+), but has not spread to distant organs (M0).
- You have not had previous rectal surgery, chemotherapy, or radiation for this cancer (except for hormone therapy).
- You are in good overall health, with a performance status of 0 or 1 (able to carry out daily activities) and a life expectancy of more than 3 years.
- Your bone marrow, liver, and kidney function are adequate, and you do not have significant heart disease, uncontrolled high blood pressure, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two treatment plans given before rectal surgery. It tests whether stronger chemotherapy alone works better than chemotherapy pills plus long-term radiation to improve outcomes for locally advanced rectal cancer.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.